评估 dextromethorphan/quinidine 在治疗亨廷顿病中易怒性的疗效
Shayan A Zadegan1,2, Olivia Calderon3, Nicholas Karagas1
1Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston), Houston, TX, USA.
Journal of Huntington's disease
|January 7, 2026
概括
德克斯特罗米多芬/氨酸 (DM/Q) 没有显著改善亨廷顿病患者的易怒性.
科学领域:
- 神经科学是一个神经科学.
- 临床药理学 临床药理学
- 神经学 神经学
背景情况:
- 亨廷顿病 (HD) 是一种进展性神经退行性疾病.
- 易怒是HD患者常见且负担重重的症状,严重影响日常生活.
- 目前没有FDA批准的药物专门针对HD中的易怒性.
研究的目的:
- 评估20/10毫克的德克斯特罗梅多芬/丁 (DM/Q) 在治疗亨廷顿病患者易怒症方面的疗效.
- 为了比较DM/Q与安慰剂对刺激症状和其他HD的行为和认知结果的影响.
主要方法:
- 这是一项双盲,安慰剂控制,随机交叉临床试验 (ClinicalTrials.gov NCT03854019).
- 参与者接受了6周的DM/Q,然后进行1周的洗,然后接受6周的安慰剂,或者反之亦然.
- 评估包括易怒度量表和问题行为评估-简短版本 (PBA-s),以及运动和认知评估.
主要成果:
- 无论是DM/Q还是安慰剂,都显示出易怒度得分的降低,两种治疗方法之间没有统计学上显著的差异.
- 在改善运动,行为或认知结果方面,DM/Q并没有表现出与安慰剂相比显著的优势.
- 18名参与者完成了这项研究,平均年龄为43.94岁.
结论:
- 与安慰剂相比,20/10毫克的德克斯特罗米多芬/丁丁 (DM/Q) 在亨廷顿病中控制易怒性方面没有显著的益处.
- 需要进一步研究更大的样本大小和新的治疗策略,以解决HD中的易怒性.
- 这项研究强调了对亨廷顿病负担重重的神经精神病症状的有效治疗的需要.
相关概念视频
Parkinson's Disease: Treatment
970
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
970
Sedatives and Hypnotics Drugs: Miscellaneous Agents
502
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
502
Antidepressant Drugs: MAOIs and Other Agents
797
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
797
Cholinergic Antagonists: Therapeutic Uses
1.3K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.3K
Antiepileptic Drugs: Potassium Channel Activators
624
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
624
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.4K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.4K


